Skip to main content

Clinical Trials

Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-695-6829.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.

Trials
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY
This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. …
This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of Dermatology hopes todevelop a better understanding of skin diseases (meaning the knowledge about how cells in theskin behave and react to medical treatments) among researchers at Northwestern University andother approved researchers. This basic knowledge is expected to help the development of moreeffective patient care and new treatment methods.
  • Consent to have specimens collected as part of a standard of care procedure
  • Have a skin disease diagnosis which researchers want samples of in order to further understand the disease
  • Qualify as a healthy volunteer (a person with no skin disease)
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info
Copy
Epidermolysis Bullosa Clinical Characterization and Outcomes Database

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, co…

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

All candidates with a clinical diagnosis of epidermolysis bullosa are eligible for this study.  The subjects can be from any age, male or female without restriction.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00202682
More Info
Copy
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)
The main goal of …
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info
Copy
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. T…
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This rash has been shown to be inflammatory in origin but is currently treated with antibiotics if it appears. The main goal of this study is to test if patients treated with steroid cream, (added) which is an anti-inflammatory medication, (added) before a rash develops have a less severe rash than patients who do not use a steroid cream before a rash develops.
Must be 18 years of age or older with a diagnosis of cancer and starting an (changed from 'and') EGFR inhibitor. During the study you must be willing to fill out a daily diary, use sunscreen and cream daily, and fill out 2 questionnaires and have photographs taken every 2 weeks for 4 visits.
Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03115567 STU00203631
More Info
Copy
The Gut and Skin Microbiome in Vitiligo Disease Progression

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and …

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits. Subjects with vitiligo will be required to follow up for additional specimen collection and questionnaire completion after six months and one year.

Volunteers over the age of 18 are eligible to participate. Study is recruiting those with and without vitiligo.
Le Poole, Isabelle CarolineLe Poole, Isabelle Caroline
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00206844
More Info
Copy
A single arm, prospective clinical study using novel wearable sensors to assess the improvement of nocturnal scratch behavior and sleep quality in children, adolescents, and adults with mild-to-severe atopic dermatitis treated with topical crisaborole (Protocol #: 052018SX)

This is a clinical rese…

This is a clinical research studyto evaluate nighttime scratching behavior and sleep quality in patients withatopic dermatitis (AD). Participants will be required to come in for onein-person visit and will be required to wear wireless sensors to tracknighttime scratching behavior and sleep quality. Use of a smartphone with ourstudy app and infrared camera to collect data, completion of daily surveysthroughout the study, as well as one remote video chat at the end of the studywill be required.

Age 2 and above with a diagnosisof mild, moderate, or severe atopic dermatitis. Participant or parent/legallyauthorized representative must be willing to operate a smartphone daily andinfrared camera nightly, as well as complete several questionnaires

Xu, ShuaiXu, Shuai
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03770858 STU00208468
More Info
Copy
(xIRB) Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of lipoproteins (substances made up of fat and protein), cholesterol, and other proteins…

The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of lipoproteins (substances made up of fat and protein), cholesterol, and other proteins in the blood.

  • Be 6 to 17 years
  • Have psoriasis, acne, or be a healthy volunteer (someone who does not have a skin condition)
  • Participants with psoriasis must have a 6 month or more history of treatment with a topical medication or have a 3 month or less history of treatment with a systemic medication (medication that works throughout the whole body)
  • Participants with acne must currently be treated with a medication called isotretinoin.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208518
More Info
Copy
Wool Clothing for Atopic Dermatitis
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to stan…
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks or begin with standard garments for 6 weeks and switch to wool garments for a further 6 weeks. Participants will attend follow-up appointments at 3, 6, 9 and 12 weeks where severity of eczema,quality of life, and any side effects will be assessed. Wool clothing and laundry detergent will be provided for the duration of the entire study.

Ages 3 months to 5 years with moderate to severe eczema as determined atinitial visit.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208730
More Info
Copy
(xIRB) Validation of Skin Hydration Sensor for Atopic Dermatitis

The main purpose of the study is to test the safety and effectiveness of a study device called Skin Hydration Sensor to measure water loss in dry skin from atopic dermatitis (eczema) or xerosis cutis (abnormally dry skin) compared to…

The main purpose of the study is to test the safety and effectiveness of a study device called Skin Hydration Sensor to measure water loss in dry skin from atopic dermatitis (eczema) or xerosis cutis (abnormally dry skin) compared to normal skin.

  • Have a diagnosis of mild, moderate, or severe atopic dermatitis (eczema) or xerosis cutis (abnormally dry skin)
  • Children (newborn to 17 years of age) and adults (17 years of age and older) are eligible
  • Individuals without eczema or abnormally dry skin are also eligible to participate
Xu, ShuaiXu, Shuai
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 2900 Foxfield Drive Suite 101
    St. Charles, IL
NCT03813472 STU00209010
More Info
Copy
XIRB-A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB photo…

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another.

12 years or older with plaque or guttate psoriasis predominantly on trunk and/or extremities. Patient needs to be willing to comply with in-office or in-home phototherapy.  
Amin, Ahmad ZAmin, Ahmad Z
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03726489 STU00209270
More Info
Copy
An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

This study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy …

This study will test if low-dose oral minoxidil has an effect on permanent chemotherapy-induced alopecia (defined as hair loss after the completion of a chemotherapy regimen that persists for over six months). In this study, you will receive the study drug; there is no placebo option. The effectiveness and safety of the treatment will be determined by a range of assessments, including biopsies, images, and subjective evaluation of perceived hair growth.

Age 18 and above with a diagnosis of permanent chemotherapy-induced alopecia and agree to use contraception for the duration of the study.

Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03831334 STU00206882
More Info
Copy
Characterization of the microbiome in cutaneous T cell lymphoma
The purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL).
  • Be between the ages of 18-89
  • Be able and willing to provide informed consent
  • You must not have cutaneous t-cell lymphoma (CTCL)
  • You must not be currently pregnant
  • You must not be on or exposed to systemic antibiotics with 4 weeks of beginning study participation
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00209226
More Info
Copy
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age)

The purpose of this re…

The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug).

You could be in this study if:

  • You are 6 to 17 years old
  • A doctor has said you have chronic plaque psoriasis
  • You have had chronic plaque psoriasis for at least 6 months
  • You have taken medication for your psoriasis, but it hasn’t worked

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03451851 STU00209613
More Info
Copy
A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these…

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience.

Additionally, researchers are interested in:

  • Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed
  • Identifying other types of conditions associated with skin disorders
  • Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition
  • Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes
  • Creating a “Biorepository Specimen Bank” with blood and saliva samples

  • Have a skin condition such as Atopic Dermatitis, Psoriasis, Alopecia, Vitiligo, Hidradenitis Suppurativa and others.
  • You will not be asked to take any medications as part of this study.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00209616
More Info
Copy
A Phase 2 Study of pembrolizumab in patients with histiocyte/dendritic cell neoplasms and biologically selected subtypes of relapsed/refractory aggressive lymphomas. (Protocol #17-448)

This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treat…

This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treating patients with an aggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that has not responded to or has come back after other treatments. The effectiveness and safety of the treatment will be determined by a range of assessments including biopsies, scans (or imaging tests), as well as general health and performance status.

Age 18 and above with a diagnosis of a histiocyte/dendritic cell neoplasm or relapsed / refractory aggressive lymphoma. Must be willing to provide tissue from a newly obtained biopsy, have normal organ and marrow function and not a candidate for potentially curative therapy at the time of enrollment.

Choi, JaehyukChoi, Jaehyuk
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03316573 STU00209675
More Info
lymphoma
Copy
Development & Preliminary Clinical Validation of Blue Light Phototherapy Systems for T-Cell Mediated Skin Diseases

The purpose of this study is to test and develop Blue Light therapy for skin diseases like psoriasis or Grover’s disease. Blue light therapy has been used for treatment of other der…

The purpose of this study is to test and develop Blue Light therapy for skin diseases like psoriasis or Grover’s disease. Blue light therapy has been used for treatment of other dermatological conditions.

This study is for adults with psoriasis vulgaris or Grover’s Disease (also known as transient acantholytic dermatosis).

Xu, ShuaiXu, Shuai
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00210472
More Info
Copy
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients with Ichthyoses
This research is being done to look at the safety and how well ustekinumab works in the treatment of individuals with ichthyosis. Participants will be in the stu…
This research is being done to look at the safety and how well ustekinumab works in the treatment of individuals with ichthyosis. Participants will be in the study up to approximately 2 years. 
Participants need to be 6 years of age or older and diagnosed with ichthyosis. 
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT04549792 STU00212072
More Info
ichthyosis
Copy
Comparison of disease knowledge in dyads of parents and their adolescents with chronic skin disorders

The main goal of this study is to understand how much parents and teenagers know about the teenagers’ chronic skin condition.

This study will enroll children ages 12 to 17 years of age with a diagnosis of psoriasis, atopic dermatitis (eczema), or ichthyosis. Both the child and participating parent must speak English.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00212092
More Info
Copy
Bullying in Pediatric Ichthyosis Patients and its Psychosocial Effects

Pediatric volunteers with ichthyosis and their parents are needed for a study to better understand the frequency and severity of bullying experienced by children with ichthyosis, and the psychosocial effects of this bullying.

Pediatric volunteers with ichthyosis and their parents are needed for a study to better understand the frequency and severity of bullying experienced by children with ichthyosis, and the psychosocial effects of this bullying.

  • Be 8-17 years old and have ichthyosis
  • Be the parent/guardian of someone 8-17 years old who has ichthyosis
  • Be able to complete a questionnaire about your/your child’s experience with bullying, mental health, and social experiences

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00212124
More Info
Copy
A PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF OQL011 ON VEGFR INHIBITOR-ASSOCIATED HAND-FOOT SKIN REACTION IN CANCER PATIENTS
This study is trying to determine whether an ointment is safe and effective for the treatment of hand-foot skin reaction induced by VEGRF inhibitors. 
Participants must be over the age of 18 and have hand-foot skin reaction after taking anti-cancer medications calls VEGRF inhibitors. 
Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT04088318 STU00211322
More Info
Copy
XIRB-Innovative Dermatology Real World Data and Research Collaborative (IMMerse)
This study aims to develop a better understanding of how psoriasis effects different groups of people. Participants will be providing information from their medical records and completing surveys online. 
Participants must be over the age of 18 and with a diagnosis of moderate to severe psoriasis. 
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00212451
More Info
Copy
Impact of immunotherapy-related skin diseases on quality of life
The purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey. 
Participants need to be 18 years and older, receiving immunotherapy, and may be experiencing a dermatologic side effect. 
Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00212205
More Info
Copy
Tape Strip Analysis in Dermatologic Diseases
The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obta…
The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples from a broad range of dermatologic diseases, which may include psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, and other rare conditions, in addition to healthy controls. 
  • Have a dermatologic disease such as psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, or other rare skin condition
  • Be a healthy volunteer (someone with no dermatologic disease)
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00213591
More Info
Copy
A Prospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the Hospital

The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.

  • Be older than 18
  • Be admitted to Northwestern Memorial Hospital or evaluated in the Emergency Department for whom an inpatient dermatology consultation is requested.

Nguyen, CuongNguyen, Cuong
  • Map it 251 E. Huron St.
    Chicago, IL
STU00212714
More Info
Copy
A Multicenter Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits in Subjects with a Variety of Dermatologic Conditions
This study is being performed to better understand the causes of skin disorders by investigating changes to genes or the way they are expressed in i…
This study is being performed to better understand the causes of skin disorders by investigating changes to genes or the way they are expressed in individuals with a skin condition. This study will also explore the microbiome of the skin. Photographs and non-invasive patch biopsy samples will be collected. 
Participants must be over the age of 18 and have a dermatologic condition. 
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00213998
More Info
Copy
XIRB-Transition Readiness Assessment in Adolescents with Genetic Chronic Skin Disorders

The main goal of this study is to understand the baseline readiness of adolescents with genetic chronic skin condition to transition to an adult model of health care.

  • Be an adolescent between 14-22 years old
  • Have a diagnosis of of a genetic chronic skin condition like ichthyosis, epidermolysis bullosa, and ectodermal dysplasia
  • Must speak English
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00214390
More Info
Copy
Deciphering the Genetics of Severe Atopic Dermatitis

The main goal of this study is to see what kinds of mutations in the genome cause atopic dermatitis, specifically which mutations lead to severe atopic dermatitis with increased infections or severity.

This study will enroll children 6 to 17 years of age with severe atopic dermatitis, their parents, and up to third-degree family members (first cousin, grandparent, great-grandparent).

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00214537
More Info
Copy
Identifying Druggable Targets of Acanthosis Nigricans via Bulk Transcriptomics
This study is being done to understand how Acanthosis Nigricans develops in order to develop targets for drugs to be developed in the future. Participants will be in the study for up to 2 weeks and will provide skin biopsi…
This study is being done to understand how Acanthosis Nigricans develops in order to develop targets for drugs to be developed in the future. Participants will be in the study for up to 2 weeks and will provide skin biopsies and blood. Photos and medical history will also be collected. 
Participants must have Acanthosis Nigricans or meet the criteria to participate as a healthy control. 
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00214401
More Info
Copy
Evaluation of haptic feedback in a novel acoustomechanic device for behavioral scratch modification in atopic dermatitis

The purpose of this study is to evaluate the performance of a soft, wearable silicone skin sensor placed on the back of the hand for detection of scratch during the day, as well…

The purpose of this study is to evaluate the performance of a soft, wearable silicone skin sensor placed on the back of the hand for detection of scratch during the day, as well as how good it is at sending out haptic feedback when you are scratching. Haptic feedback is the use of vibrations to notify the user; it is the same concept as vibrations on your phone when you get an alert or notification. We hope to be able to help people recognize when they are scratching during the day if it is habitual or subconscious and hopefully decrease the amount of scratching.

  • Age 18 and older, or consent from a parent / guardian to participate
  • Have a diagnosis of atopic dermatitis (eczema) or cutaneous T-cell lymphoma
Xu, ShuaiXu, Shuai
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00214800
More Info
Copy
Open Label Treatment of Beremagene Geperpavec (B-VEC)

The purpose of this study is to provide use of the gene therapy study drug Beremagene Geperpavec (B-VEC) for participants who have previously completed the parent phase 3 study or for those who were unable to participate in the phase 3 study an…

The purpose of this study is to provide use of the gene therapy study drug Beremagene Geperpavec (B-VEC) for participants who have previously completed the parent phase 3 study or for those who were unable to participate in the phase 3 study and would now like to receive treatment with the study drug.

  • Be willing and able to give consent/assent
  • Have a clinical diagnosis of epidermolysis bullosa
  • Have confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1
  • Be 6 months of age and older at the time of informed consent/assent
  • Women of childbearing age must be willing to use reliable birth control method throughout the treatment duration and for 3 months following the last treatment application

Paller, AmyPaller, Amy
STU00215480
More Info
Copy
Medical Outcomes in CHronic Inflammatory skin disease (MOCHI)

The purpose of this study is to collect characteristic data from patients with atopic dermatitis (AD) or other chronic inflammatory skin disorders (CISDs), such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vu…

The purpose of this study is to collect characteristic data from patients with atopic dermatitis (AD) or other chronic inflammatory skin disorders (CISDs), such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, cutaneous T cell lymphoma, psoriasis, hidradenitis through an online survey.

This study is for individuals aged 18 and over who have been diagnosed with atopic dermatitis (i.e. eczema) or other chronic inflammatory skin diseases such as chronic urticaria, generalized pruritus, prurigo nodularis, pemphigus vulgaris, bullous pemphigoid, mycosis fungoides, cutaneous T cell lymphoma, psoriasis, and hidradenitis.

Chovatiya, RajChovatiya, Raj
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00215502
More Info
Copy
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris

The purpose of this study is to determine the highest dose of the study drug that can be given safel…

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.

  • Must be at least 18 years of age
  • Have a confirmed diagnosis of mucosal-dominant pemphigus vulgaris or have a prior positive demoglein 3-ELISA result (a pemphigus vulgaris diagnostic tool) and confirmed by biopsy at the screening visit
  • Have pemphigus vulgaris that has previously been inadequately managed by at least one prior standard therapy
Zhou, AlanZhou, Alan
NCT04422912 STU00214626
More Info
Copy
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
The purpose of this study is to determine if an investigational cream, ruxolitini…
The purpose of this study is to determine if an investigational cream, ruxolitinib cream (0.75% and 1.5%strengths), is safe and effective to treat atopic dermatitis (eczema) in children.

  • Age 2 - 11 years
  • History of atopic dermatitis (eczema) for at least 3 months
  • Are able to attend regular visits over a 14-month period
  • Willing to discontinue use of other eczema medications during the course of the study

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216006
More Info
Copy
Open Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Pediatric Subjects with Extensive Atopic Dermatitis
The purpose of this study is to assess the safety and tolerability (how well treatment is tolerated) of tapinarof cream, 1% (a topical …
The purpose of this study is to assess the safety and tolerability (how well treatment is tolerated) of tapinarof cream, 1% (a topical treatment) when applied once daily for 27 days on the surface of the skin of individuals with Atopic Dermatitis (eczema).

  • Have been diagnosed with eczema
  • Are male or female between 2 and 17 years of age
  • Have eczema that covers over 25% of the body, not including the scalp
  • Have eczema present for at least 3 months for ages 2 to 5 years old; or have eczema present for at least 6 months for ages 6 years old and above
  • Be able to have a parent(s), or legal representative, provide written informed consent / assent
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216207
More Info
Copy
Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants

The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug…

The purpose of this study is to find out how long ustekinumab stays in and acts in the body. It is investigating how much ustekinumab is present in people's bodies (called a "drug level"). This is measured by blood tests. Another purpose is to find out if ustekinumab can cause side effects, which are unexpected or unwanted reactions from taking a drug. Study participation is a maximum of 16 weeks. No study drug will be provided for this study, only study procedures (blood draw, specific vital signs) will be performed.

  • Be between 6-18 years of age with a diagnosis of juvenile psoriatic arthritis
  • Be between 6 to <18 years of age, with a diagnosis of pediatric psoriasis
  • Have started ustekinumab treatment for at least 16 weeks prior to participating and have received 3 or more doses of ustekinumab prior to participating
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216219
More Info
Copy
Irritancy and Allergenicity of Synthetic-Melanin-Based Hair Dye Components

The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a…

The purpose of this study is to determine if individuals with PPD allergies react to synthetic melanin (the pigment that gives your skin its color) or the compounds that comprise it. Most commercial hair dyes contain PPD, a compound that is known to cause allergic reactions. This study aims to investigate the possibility of using synthetic melanin as a hair dye as an alternative.

  • Healthy adults ages 18 years or older with skin allergy to PPD
  • Able to list all current medications and medical conditions
  • Capable of giving informed consent.

Gianneschi, NathanGianneschi, Nathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00213915
More Info
Copy
A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your bl…

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.

  • Be 2-17 years old
  • Have a clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months
  • Have involvement of plaque psoriasis on at least 3% of the body, excluding the scalp
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216645
More Info
Copy
TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell lymphoma

The purpose of this study is to evaluate the effectiveness and s…

The purpose of this study is to evaluate the effectiveness and safety of a new experimental drug named lacutamab (IPH4102).

  • Be at least 18 years of age
  • Be diagnosed with one of the following types of cancer: Sezary Syndrome (SS), or mycosis fungoides (MF)
  • Have received at least two prior systemic therapies (treatments that use substances that travel through the bloodstream, reaching and affecting cells all over the body)
  • Prior treatment with mogamulizumab
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00215713
More Info
Copy

Follow Dermatology on